Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV

Wspolczesna Onkologia

Volumn 16, Issue 6, 2012, Pages 532-545

  Cybulska Stopa, Bozena ^a   Skoczek, Marta ^b   Ziobro, Marek ^a   Świtaj, Tomasz ^c   Falkowski, Sławomir ^c   Morysiński, Tadeusz ^c   Hetnał, Marcin ^a   Cedrych, Ida ^a   Rutkowski, Piotr ^c  

^a Centre of Oncology   (Poland)

^b Szpital Specjalistyczny JP2 ^*  (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Melanoma; Metastases; Outcomes; Prognostic factors; Therapy

Indexed keywords

ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; FLUOROURACIL; INTERLEUKIN 2; LACTATE DEHYDROGENASE; MEDROXYPROGESTERONE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84872593545     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.32487     Document Type: Article

References (45)

1. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W. Nowotwory złośliwe w Polsce w 2005 roku. Centrum Onkologii - Instytut 2007.
2. Ruka W, Krzakowski M, Placek W, et al. Czerniaki skóry - zasady postȩpowania diagnostyczno-terapeutycznego Onkol Prak Klin 2009; 5, 1: 20-32
3. Balch CM, Gershenwald JE, Soong S, et al. Final Version of 2009 AJCC Melanoma Staging and Classification J Clin Oncol 2009; 27: 6199-206.
4. Allen LE, Kupelnic B, Kumashiro D, et al. The combination of chemotherapy with Il-2 and alpha IFN is more active than chemotherapy or immunotherapy alone in patients withmetastatic melanoma: a meta-analysis of 7711 patients with metastatic melanoma. Proc Am Soc Clin Oncol 1997; 16: 1781, p494a.
5. Eton O, Legha SS, Bedikian AY, et al. Sequential Biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomised trials. J.Clin Oncol 2002; 20: 2045-52. (Pubitemid 34408794)
6. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostis Factors in M: 3782-93.
7. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201.
8. Lotze MT, Dallal RM, Kirkwood JM, et al. Cutaneous melanoma. in: Cancer principles &Practice of Oncology. De Vita VT, Hellman S, Rosenberg SA (eds.). Lippincot Wiliams & Wilkins. Philadelphia 2001, 2020.
9. Buzaid AC, Bedikian A, Houghton AN. Systemic chemotherapy and biochemotherapy, in Cutaneous melanoma. Balch CM, Houghton AN, Sober MD (eds.). Quality Medical Publishing, Inc. St. Louis, Missouri 1998, 406-18.
10. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-34. (Pubitemid 351264344)
11. Lui P., Cashin R., Machado M., et al. Treatments for metastatic melanoma: Synthesis of evidens from randomized trials. Cancer Treat Rev 2007; 33: 665-80. (Pubitemid 350082665)
12. Bhatia S., Tykodi S., Thompson J. Treatment of metastatic melanoma: Overview. Oncology 2009; 23960: 488-96.
13. Middleton MR, Grob JJ, Aaroson N, et al. Randomized phase III study of temozolomide versus dacarbazine in treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166. (Pubitemid 30036349)
14. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 Suppl 1: S11-4.
15. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-16. (Pubitemid 29318842)
16. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984 Nov;68(11):1403-5. (Pubitemid 15222028)
17. Lattanzi SC, Tosteson T, Chertoff J, et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995; 5: 365-9.
18. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51. (Pubitemid 29415231)
19. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64: 2024-9. (Pubitemid 19280399)
20. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. 2006; 17: 571-7.
21. Rutkowski P, Nowecki ZI, Dziewirski W, et al. Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg 2010; 36: 868-76.
22. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25: 5426-34. (Pubitemid 350232219)
23. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of Patients Treated Systemically for Disseminated melanoma. J Clin Oncol 1998; 16: 1103-1111 (Pubitemid 28108747)
24. Czerniak zlośliwy. Skowronek J, Mackiewicz A, Żygulska-Mach H (ed.). Termedia, Poznań 1998.
25. Balch CM, Soong SJ, Gershenwakd JE, et al. Prognostic factors analisis of 17600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34 (Pubitemid 32786275)
26. Sirott MN, Bajorin DF, Wong GY, et al. Prognostic Factors in Patients with Metastatic Malignant melanoma. Cancer 1993; 72: 3091-8. (Pubitemid 23335058)
27. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79: 2345-53. (Pubitemid 27251017)
28. Unger JM, Flaherty LE, Liu PY, Albain KS, Sondak VK. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 2001; 91: 1148-55. (Pubitemid 32295420)
29. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 2000; 10: 81-92. (Pubitemid 30127833)
30. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 6747-55. (Pubitemid 46190270)
31. Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Oncologist 2009; 14: 995-1002.
32. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995-3005. (Pubitemid 23145529)
33. Presant CA, Bartolucci AA. Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group Experience. Cancer. 1982; 49: 2192-6. (Pubitemid 12100757)
34. Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 2001; 19: 3194-202. (Pubitemid 32591436)
35. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1: 126-34. (Pubitemid 14176801)
36. Savoia P, Fava P, Osella-Abate S, Nardň T, Comessatti A, Quaglino P, Bernengo MG. Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma Centre. Melanoma Res 2010; 20: 227-32.
37. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009; 27: 3489-95.
38. Laveau F, Picot MC, Dereure O, Guilhou JJ, Guillot B. Metastatic melanoma of unknown primary site. Ann Dermatol Venereol 2001; 128: 893-8. (Pubitemid 32946334)
39. Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol 1998; 9: 419-22. (Pubitemid 28273035)
40. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48. (Pubitemid 32786276)
41. Ryan L., Kramar A., Borden E. Prognostic factors in Metastatic melanoma. Cancer 1993; 71: 2995-3005 (Pubitemid 23145529)
42. Falkson CI, Falkson HC. Prognostic factors in metastatic malignant melanoma. An analysis of 236 patients treated on clinical research studies at the Department of Medical Oncology, University of Pretoria, South Africa from 1972-1992. Oncology 1998; 55: 59-64. (Pubitemid 128707625)
43. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am 2003; 83: 109-56. (Pubitemid 36384363)
44. Young SE, Martinez SR, Essner R. The role of surgery in treatment of stage IV melanoma. J Surg Oncol 2006; 94: 344-51. (Pubitemid 44330859)
45. Thomson DB, Adena M, McLeod GR, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133-8. (Pubitemid 23156589)